Among older adults, three measures of adiposity conferred elevated risk for HF in patients with diabetes but not in those without diabetes, according to data published in Circulation.“Obesity affects over one-third of adults in the United States and is a significant risk factor for diabetes and HF,” Kershaw V. Patel, MD, preventive cardiologist at Houston Methodist DeBakey Heart and
TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years Medtronic plc a global leader in healthcare technology, today unveiled five-year clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation Trial, which was presented as a Late Breaking Clinical Trial at the 33 rd Transcatheter Cardiovascular Therapeutics conference, the .
The global trial evaluated the long-term results of the medtech giant’s first- and second-generation TAVR systems, under its CoreValve and Evolut R platforms. The results illustrate the long-term benefits of the procedure, which aims to shorten hospital stays and quicken recovery times in the near term.
Cardiol Therapeutics Inc. a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that it has received approval from Health Canada to proceed with the Company's Phase II, multi-center, double-blind, randomized, placebo-controlled trial designed to study the safety and tolerability of CardiolRx™ as well .
Relatively few patients undergoing surgery for acute type A aortic dissection receive recommended imaging surveillance afterward, a new study suggests.